CABALETTA BIO, INC. Defined Contribution Plan, Cost
CABALETTA BIO, INC. (CABA) reported Defined Contribution Plan, Cost of $1.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-23
- CABALETTA BIO, INC. defined contribution plan, cost for fiscal 2025 was $1.06M, a 18.90% increase from fiscal 2024.
- CABALETTA BIO, INC. defined contribution plan, cost for fiscal 2024 was $894.00K, a 71.59% increase from fiscal 2023.
- CABALETTA BIO, INC. defined contribution plan, cost for fiscal 2023 was $521.00K, a 48.43% increase from fiscal 2022.
- CABALETTA BIO, INC. defined contribution plan, cost for fiscal 2022 was $351.00K, a 37.11% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $1.06M 10-K · filed 2026-03-23 |
| 2024-12-31 | $894.00K 10-K · filed 2026-03-23 |
| 2023-12-31 | $521.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $351.00K 10-K · filed 2024-03-21 |
| 2021-12-31 | $256.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $203.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $74.00K 10-K · filed 2021-03-16 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |